Howard Kaufman
MD, FACS
Chief Medical Officer
👥Biography 个人简介
Howard Kaufman led the pivotal trials of talimogene laherparepvec (T-VEC), the first FDA-approved oncolytic virus, demonstrating that intratumoral viral therapy can inflame cold tumors and synergize with checkpoint inhibitors. He continues to advance intratumoral strategies to convert immune-cold lesions into responsive disease.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Howard Kaufman 的研究动态
Follow Howard Kaufman's research updates
留下邮箱，当我们发布与 Howard Kaufman（Ankyra Therapeutics / Harvard Medical School）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment